Children with Down syndrome (DS) are at a 20-fold increased risk for acute lymphoblastic leukemia (ALL). Compared to children with ALL and no DS (non-DS-ALL), those with DS and ALL (DS-ALL) harbor uncommon genetic alterations, suggesting DS-ALL could have distinct biological features. Recent studies have implicated several genes on chromosome 21 in DS-ALL, but the precise mechanisms predisposing children with DS to ALL remain unknown. Our integrated genetic/epigenetic analysis revealed that DS-ALL was highly heterogeneous with many subtypes. Although each subtype had genetic/epigenetic profiles similar to those found in non-DS-ALL, the subtype distribution differed significantly between groups. The Philadelphia chromosome-like subtype, a high-risk B-cell lineage variant relatively rare among the entire This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
| INTRODUC TI ON
Children with DS harbor one extra copy of chromosome 21. Among other congenital deficits and disease susceptibilities, children with DS are at a 20-fold increased risk for ALL. 1 Compared to ALL in children without DS (non-DS-ALL), children with DS and ALL (DS-ALL) show uncommon genetic alterations, 2 such as mutations in JAK2, NRAS, and KRAS as well as CRLF2 overexpression, suggesting that certain tumorigenic or other disease-related processes could be unique to DS-ALL. Consistent with distinct ALL pathomechanisms in DS, DS-ALL patients have generally worse prognosis than non-DS-ALL patients. Therefore, it is critical to identify factors contributing to enhance ALL propensity and severity in DS.
Genes on chromosome 21 are obvious candidates. Indeed, recent studies have implicated HMGN1 3 and DYRK1A 4 overexpression in DS-ALL.
To better understand DS-ALL molecular pathogenesis, we carried out an integrated genetic/epigenetic analysis. Expression and methylation analyses revealed high subtype heterogeneity in DS-ALL. Although each subtype had expression and methylation profiles similar to corresponding non-DS-ALL subtypes, subtype frequency distribution differed significantly between patient groups.
The hypermethylation of RUNX1 on chromosome 21 was unique to DS-ALL, which could explain the increased incidence of BCP-type ALL in DS.
| MATERIAL S AND ME THODS

| Patients and materials
Forty-three patients with DS-ALL (Table S1 ), 38 patients with non-DS-ALL (Table S2) , and 18 DS patients without ALL or AML (Table S3) were enrolled in this retrospective study. The 43 DS-ALL patients included one large cohort (n = 31) from the JACLS as well as patients from various hospitals in Japan. The 38 non-DS-ALL patients were from the University of Tokyo Hospital. Peripheral blood and bone marrow samples were collected after written informed consent was obtained from legal guardians according to protocols approved by the Human Genome, Gene Analysis Research Ethics Committee of the University of Tokyo, and other participating institutions. All protocols conformed to the tenets of the Declaration of Helsinki.
| Next-generation sequencing
Next-generation sequencing was carried out using the Illumina HiSeq 2000, 2500, or MiSeq platform (Illumina) with a standard 100-bp paired-end read protocol according to the manufacturer's instructions. 5 
| RNA sequencing
High-quality RNA samples isolated by Agilent TapeStation (Agilent) were available from 25 DS-ALL patients (RNA integrity number equivalent greater than 5.5). These samples were used to prepare libraries for RNA sequencing using the NEBNext Ultra RNA library prep kit for the Illumina platform (New England BioLabs). Fusion transcripts were detected by Genomon version 2.5.0 and filtered by excluding fusions mapping to repetitive regions. Normalized count data obtained by the variance-stabilizing transformation function of the R package DESeq2 were used for clustering analysis. Prior to clustering analysis, the data were filtered to remove gene sets deemed unrelated to disease, such as those from sex-determining regions of X and Y chromosomes and genes (Table S4) (Table S6 ).
| Validation of fusion genes detected by RNA sequencing
Novel in-frame fusion transcripts were validated by RT-PCR followed by Sanger sequencing (Table S7 ).
| Detection of the Ph-like signature
We defined a ROSE gene set (Table S8 ), including the top 25 genes in clusters R1-R8. 7 Ward's hierarchical clustering method was then used for clustering analysis of the ROSE gene set. As reported, 7 samples in cluster R8 showed a signature similar to Philadelphia chromosome-positive ALL and were thus labeled Ph-like. To detect other samples with a Ph-like signature, we undertook hierarchical pediatric ALL population, was the most common form in DS-ALL. Hypermethylation of RUNX1 on chromosome 21 was also found in DS-ALL, but not non-DS-ALL. RUNX1 is essential for differentiation of blood cells, especially B cells; thus, hypermethylation of the RUNX1 promoter in B-cell precursors might be associated with increased incidence of B-cell precursor ALL in DS patients.
K E Y W O R D S
acute lymphoblastic leukemia, children, Down syndrome, epigenetic analysis, genetic analysis clustering of 25 DS-ALL (Table S1 ) and 118 non-DS-ALL samples (Tables S2 and S6 ) based on genes (Table S9 ) significantly upregulated (adjusted P < .0001) in samples previously labeled Ph-like in R8. 
| DNA methylation analysis
| Bisulfite conversion of RUNX1
To confirm RUNX1 methylation in DS patients without ALL or AML, bisulfite sequencing was carried out using nested primers (forward, 5′-tcttgaaaagaagaaacagacca-3′; reverse, 5′-agtaaattctagcattactccaggga-3′). Genomic DNA (500 ng) was bisulfite-modified using the EpiTect Plus DNA bisulfite kit (Qiagen) according to the manufacturer's instructions. 
| Targeted capture sequencing
| Copy number analysis
DNA samples extracted from peripheral blood or bone marrow were processed using MLPA for the JACLS samples and SNP array analysis for the other samples. The MLPA was carried out using the SALSA MLPA probemix P335-B1 ALL-IKZF1 kit according to the manufacturer's instructions (MRCHolland). The SNP array analysis was undertaken using the Affymetrix GeneChip 250K Nsp or CytoScan HD (Affymetrix), according to the manufacturer's protocol.
| Mutations in non-DS-ALL samples
Among the 118 samples used for RNA sequencing, DNA was available for 42 paired normal samples, which were evaluated using whole-exome sequencing. The mutations in the remaining 76 samples, for which paired normal DNA was not available, were called by the RNA sequencing results.
| RE SULTS
| Expression analysis
Initial next-generation sequencing analysis of 25 DS-ALL samples (Table S1 ) identified 19 fusions (Table S10) , including 15 frequently reported in pediatric BCP-ALL, as well as 4 novel fusions. Among common fusions previously identified in ALL, P2RY8-CRLF2 was detected in 9 samples; IGH-CRLF2 was not detected in our cohort.
Among novel fusions, PDGFA-TTYH3 was detected in 2 samples.
Two DS-ALL samples with t(14;19)(q32;q13) 11 and t(8;14)(q11;q32) 12 showed high CEBPA and CEBPD expression levels, respectively ( Figure S1 ). These samples were assumed to harbor IGH-CEBPA and IGH-CEBPD fusions, respectively, because both karyotypes involved IGH at 14q32. These fusions are rare in non-DS-ALL, but could be more common in DS-ALL. 12, 13 To characterize the unique expression profiles of DS-ALL, we applied hierarchical clustering analysis ( Figure 1 and Table S5 ) including the 25 DS-ALL and 118 non-DS-ALL samples (expression cohort). These non-DS-ALL samples included several subtypes, such as the ETV6-RUNX1 fusion and HeH (Tables   S2 and S6 ). We also identified 8 samples with PAX5 abnormalities in the absence of other genetic alterations, which we defined as "PAX5altered." Unsupervised hierarchical clustering of the entire ALL sample population yielded 6 clusters (E1-E6), and DS-ALL samples fell into 4 clusters, with significantly enrichment in E6 (Table S11 ).
Cluster E3 was heterogeneous and contained several ALL subtypes, including MLL-rearranged, TCF3-HLF, IGH-DUX4, MEF2D-rearranged, and PAX5-altered. The PAX5-altered samples fell into clusters E3 and E6. All DS-ALL samples with ETV6-RUNX1 fell into cluster E4, which also included all non-DS-ALL samples with the ETV6-RUNX1 fusion.
Additionally, E4 included one DS-ALL sample without ETV6-RUNX1.
Six DS-ALL fell into cluster E5, which also included most non-DS-ALL samples with HeH. Among these 6 DS-ALL cases, only 1 had HeH. Cluster E6 was characterized by the presence of BCR-ABL1 fusions, Ph-like expression profiles, and CRLF2 fusions.
To detect the Ph-like signature, we clustered the expression cohort by gene sets using the ROSE method 7 ( Figure S2 and Table   S8 ), which revealed that 7 DS-ALL samples had the Ph-like signature. Altogether, expression analysis revealed that DS-ALL samples were highly heterogeneous, but individual subtypes showed expression patterns similar to corresponding non-DS-ALL subtypes. Alternatively, the frequency distribution differed between groups.
Although it is reasonable to speculate that genes on chromosome 21 could be associated with DS-ALL development, surprisingly no genes on chromosome 21, such as HMGN1 or DYRK1A, showed significantly higher expression in DS-ALL (Table S12 ).
| DNA methylation analysis
We then compared DNA methylation status between DS-ALL and In accordance with expression analysis, DS-ALL samples were clustered in subtypes similar to those of the non-DS-ALL samples by methylation analysis. However, the methylation levels of several genes, including RUNX1 and KDM2B, were higher in the DS-ALL samples than non-DS siblings or mothers. 14 Although methylation clustering revealed no distinct DS-ALL subtypes, the direct comparison of methylation status revealed that the P1 promoter region 15 of RUNX1 was hypermethylated in DS-ALL, but not in non-DS-ALL ( Figure 3A and Table S14 ). Methylation of RUNX1 promoters was higher in all DS-ALL subtypes compared to corresponding non-DS-ALL subtypes except for ETV6-RUNX1, although the sample size of several subtypes, such as Ph-like or PAX5-altered, were small in non-DS-ALL ( Figure S6 ). Next, we used the most significant probe (cg22698744) to compare ALL samples with CD19 + B cells and CD19 − B cells from fetal bone marrow samples, 16 Figure 3B ).
However, RUNX1 promoters were also hypermethylated in DS patients without ALL ( Figure S7 ). RUNX1 promoter methylation was also higher in adults than fetuses.
Thus, consistent with a previous report, 14 the RUNX1 promoter appears congenitally hypermethylated in DS. The RUNX1 isoform transcribed from the P1 promoter is expressed predominantly in hematopoietic cells. 18 As RUNX1 is essential for the differentiation of B cells, hypermethylation of the RUNX1 promoter could be associated with increased BCP-ALL incidence in DS.
| Mutation and copy number analysis
To investigate the relationships among expression, methylation, and genetic status, we undertook mutational (Table S15 ) and copy number analyses (Tables S16 and S17) on 43 DS-ALL samples previously analyzed for expression ( Figure 4A ) or DNA methylation ( Figure 4B ).
In addition, we included the mutational analysis results (Tables S18 and S19) of 118 non-DS-ALL samples (expression cohort). Six of 25 samples with CRLF2 fusions harbored JAK2 mutations. As all DS-ALL samples with JAK2 mutations and CRLF2 fusions in the expression analysis had Ph-like signatures similar to non-DS-ALL, 19 ,20 all 6 DS-ALL samples in the mutation cohort were labeled as Ph-like. In cluster E5, one non-DS-ALL sample with a JAK2 mutation and CRLF2 fusion was not labeled as Ph-like.
To detect other samples with Ph-like signatures, we carried out a hierarchical clustering of expression cohort samples (Tables S1,   S2 , and S6), based on the significantly highly expressed (adjusted P < .0001) genes (Table S9 ) in cluster R8 ( Figure S8 ). This analysis Figure S9 ). The expression levels of PAX5 exons 2-5 were higher than other exons ( Figure S10 ), suggesting the expression of structurally aberrant PAX5 protein or a loss of function.
In addition, the expression profile of this particular sample (DS- 15) was similar to other PAX5-altered samples from the expression analysis and so was categorized as PAX5-altered.
With the exception of PAX5 deletion, PAX5 status has not been evaluated previously in DS-ALL. Our results raised the possibility that miscellaneous aberrations, such as amplifications or fusions, as well as deletions, might occur in DS-ALL. Furthermore, several of the PAX5-altered DS-ALL samples, including those with PAX5 amplification, were clustered in E3. Although various PAX5 alterations, including fusions, amplifications, or mutations, were detected in BCP-ALL, the expression profiles of these samples were similar regardless of PAX5 alterations without PAX5 deletions. 23 In our cohort, our defined PAX5-altered samples were also clustered into the single cluster, E3, although our sample size was small and our analysis might not be precise. Because PAX5 deleted samples were not necessarily clustered into E3 and were detected in 4 clusters, PAX5 deletion would have different pathogenicity from other PAX5 alterations. PAX5 deletions decrease the expression of PAX5, however, other PAX5 alterations might express aberrant PAX5 protein.
One DS-ALL sample (DS-13), without the ETV6-RUNX1 fusion in cluster E4, had homozygous deletions of ETV6 ( Figure S11 ), suggesting an ETV6-RUNX1-like signature. 24 Cluster M4 included 2 DS-ALL samples (DS-10 and DS-13) without the ETV6-RUNX1 fusion. Copy number analysis revealed one more sample with an ETV6-RUNX1like signature ( Figure S12 ). Although DS-10 was not available due to poor RNA quality, copy number analysis showed that DS-10 harbored deletions of several genes, including ETV6 and ARPP21, 25 suggesting that DS-10 was also the ETV6-RUNX1-like signature.
| D ISCUSS I ON
Although incidence of a Ph-like signature was high in DS-ALL, especially in children younger than 10 years old, the genetic profile of DS-ALL was highly heterogeneous ( Figure 5 ). Although the expression and DNA methylation analyses revealed many similarities between DS-ALL and non-DS-ALL, the subtype profile of DS-ALL was distinct, with lower frequencies of ETV6-RUNX1 and HeH subtypes 26 and a high incidence of a Ph-like signature, especially There were also discrepancies in cluster designation based on differential expression and DNA methylation. Differences in gene expression could stem from mutations, the presence of chimeric genes, and (or) DNA methylation. Previous studies reported that the frequencies of MLL-rearranged, BCR-ABL1, ETV6-RUNX1, and HeH subtypes were low in DS-ALL; however, considering that ALL risk is 20-fold higher in DS, 1 the incidence rates of these subtypes as HMGN1 and DYRK1A. In addition, as our analysis revealed, F I G U R E 5 Genetic landscape of Down syndrome and acute lymphoblastic leukemia (DS-ALL). A, Genetic landscape of DS-ALL combined with clinical information. The NCI criteria (standard risk [SR] or high risk [HR]), sex, and outcomes (alive or dead) together with subtypes, the affected genes, and the types of genomic aberrations are shown by colors as indicated. IKZF1plus was defined as IKZF1 deletions co-occurring with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion. We detected Ph-like, ETV6-RUNX1-like, PAX5 alteration, IGH-CEBPA fusion, and IGH-CEBPD fusion in addition to known subtypes such as ETV6-RUNX1, high hyperdiploid, dic(9;20), TCF3-PBX1, and BCR-ABL1. Samples are ordered by biological subtypes. B, The relation between mutational status and biological subtypes in DS-ALL samples. The upper half of this figure shows already known genetic alterations in DS-ALL; the lower half shows subtypes of ALL detected by our analysis. All samples with JAK2 mutations and CRLF2 fusions have the Philadelphia chromosome (Ph)-like signature. In contrast, several subtypes of DS-ALL have mutations of RAS pathway genes hypermethylation of RUNX1 promoter is also a potential predisposing factor. RUNX1 is the differentiation factor from common lymphoid progenitors to pre-pro-B cells and hypermethylation of the RUNX1 promoter is predicted to decrease RUNX1 expression 28 in common lymphoid progenitors. Furthermore, chromosomal instabilities 29 caused by aneuploidy in DS patients might be associated with ALL development. These genetic and epigenetic factors could act synergistically to promote DS-ALL. Several genes, including RUNX1, were also shown to be hypermethylated in DS patients with myeloid leukemia or transient myeloproliferative disorder compared to DS noncancerous fetal liver mononuclear cells. 30 However, our comparison of DS-ALL and non-DS-ALL samples revealed similar expression levels of RUNX1, HMGN1, and DYRK1A as well as other chromosome 21 genes between the 2 groups, suggesting that the roles of these genes could be limited to the development of ALL and not afterwards. In addition, hypermethylation of the RUNX1 promoter was not detected in several subtypes, including ETV6-RUNX1, some Phlike, and some B-other samples, suggesting that these subtypes have unique molecular pathomechanisms independent of RUNX1.
In our cohort, DS-ALL prognosis was worse than non-DS-ALL prognosis ( Figure S13A,B) , possibly due to the greater sensitivity of DS-ALL patients to chemotherapy side-effects and higher treatment- The major limitation of this study is the small DS-ALL sample size, which precluded direct comparisons of many subtypes between groups and limited whole-genome sequencing. Thus, our findings must be verified by a prospective study involving a large cohort.
In conclusion, we confirmed that DS-ALL is highly heterogeneous with many subtypes. Although subtype expression and methylation profiles were similar to non-DS-ALL, subtype frequencies differed significantly between groups. The Ph-like subtype was the most common in DS-ALL, accounting for approximately one-third of all samples. Hypermethylation of the RUNX1 promoter was also a unique characteristic of DS-ALL, and so could explain the increased ALL incidence in DS.
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